Contact

Telers, 60

17820 Banyoles, Spain

Equipment for the production of COVID-19 vaccines


Customer Customer

The customers were pharmaceutical companies tasked with mass producing the main vaccines in the fight against COVID-19.

The customers had been authorised to produce the vaccine by the main pharmaceutical companies that had developed them and needed to produce them quickly in order to start vaccinating the population as soon as possible.

Project Project

They needed sterilisable equipment to cool and keep the vaccine homogeneous before entering the filling machine.

The main constraint for these two customers was the lead time for the production of the PED reactors and the supplier’s expertise in sterile equipment for pharmaceutical products.

Equipment for the production of COVID-19 vaccines
  • Equipment for the production of COVID-19 vaccines
  • Equipment for the production of COVID-19 vaccines
  • Equipment for the production of COVID-19 vaccines
  • Equipment for the production of COVID-19 vaccines
  • Equipment for the production of COVID-19 vaccines

INOXPA was the only supplier able to provide a solution to their needs in terms of quality, price and delivery times.

  • Equipment for the production of COVID-19 vaccines
  • Equipment for the production of COVID-19 vaccines
  • Equipment for the production of COVID-19 vaccines
  • Equipment for the production of COVID-19 vaccines
  • Equipment for the production of COVID-19 vaccines

INOXPA was the only supplier able to provide a solution to their needs in terms of quality, price and delivery times.

Why INOXPA? Why INOXPA?

The customers had approached several competitors because they needed equipment with the fastest delivery time possible for producing their vaccines.

Thanks to our short delivery times, highly competitive prices and supreme product quality, the customers chose to install our equipment.

Our proven experience in the manufacture and installation of similar equipment for the pharmaceutical industry was also instrumental in convincing the customers to choose our solutions.

The customers used to rely on a hot purified water cleaning system without detergent, which is not compatible with vaccine production. INOXPA offered them a CIP/SIP system with detergent plus drying system, making it ideal for cleaning the equipment and all other elements used to produce the vaccine.


Installation characteristics Installation characteristics

First installation:

  • 3 x 200L mobile reactors with BMA magnetic agitators.
  • 1 x CIP/SIP system to clean, sterilise and dry the production equipment.
  • Automation with Siemens PLC with FDA-compliant CFR Part 11 licence.

 

Second installation:

  • 8 x 1000L mobile reactors.
  • Automation with Siemens PLC with FDA-compliant CFR Part 11 licence.
  • 2 x CIP/SIP systems to clean, sterilise and dry the production equipment.

Special features Special features

Key highlights:

  • The INOXPA team acted swiftly in delivering an offer in response to the customers’ requests that was highly competitive in terms of both price and delivery time.
  • We had the opportunity to showcase our know-how, experience and some similar equipment, helping us to earn the customer’s trust ahead of the first order.
  • All of our equipment boasts a high quality finish thanks to close collaboration between different engineering and production centres of the INOXPA Group.
  • Both customers were delighted with the results, with one of them expanding production and trusting only INOXPA to deliver the new production and cleaning equipment.

Request information

Equipment for the production of COVID-19 vaccines